Talk:4-Me-αET: Difference between revisions

Line 67:

|OralROA=true

|OralROA_Collapsed=~~true~~

|OralROA_Collapsed=false

|OralROA_Caption=

|OralROA_Bioavailability=

Line 226:

==History and culture==

~~{{historyStub}}~~

4-Me-αET, or 4-methyl-α-ethyltryptamine, is a synthetic tryptamine derivative that was first synthesized by the American chemist Alexander Shulgin in the 1970s. Shulgin, who was known for his work in the field of psychoactive substances, first synthesized 4-Me-αET in 1976 and described it as a "very active" psychedelic in his book "TiHKAL" (Tryptamines I Have Known And Loved).

==Chemistry==

4-Me-αET, also known as 4-methyl-α-ethyltryptamine, is a tryptamine derivative and a member of the family of serotonergic psychedelics. The chemical structure of 4-Me-αET includes an indole ring, a methyl group attached to the nitrogen atom of the indole ring, and an ethyl group attached to the alpha-carbon of the indole ring.

The presence of the methyl group and the ethyl group in 4-Me-αET alters the structure and properties of the tryptamine core, which may affect its biological activity and pharmacological properties. The methyl group is a hydrophobic group that increases the lipophilicity of the molecule, making it more soluble in fat and less soluble in water. The ethyl group is a larger alkyl group that can affect the steric properties of the molecule, potentially altering its binding to biological targets.

In terms of its pharmacological activity, 4-Me-αET is believed to act as a partial agonist of the 5-HT2A and 5-HT2C receptors, which are involved in the regulation of mood, cognition, and perception. The exact mechanism of action of 4-Me-αET is not fully understood, but it is thought to exert its effects by binding to and activating these receptors, leading to changes in neural activity and neurotransmitter release.

Overall, the chemistry of 4-Me-αET is characterized by its unique structure, which includes a tryptamine core with a methyl and ethyl group attached to it, and its ability to interact with and modulate the activity of serotonergic receptors in the brain.

==Pharmacology==

~~{{pharmacology}}~~

Despite its apparent psychoactive properties, 4-Me-αET remained relatively unknown and unexplored in the scientific community for many years, likely due to its status as a synthetic drug and the limited research resources available for the study of psychoactive substances. However, in the late 2000s and early 2010s, there was renewed interest in the potential therapeutic applications of psychedelics, and 4-Me-αET was among the substances that were investigated.

One study published in 2010 by a group of researchers in Japan investigated the behavioral effects of 4-Me-αET in rats, and found that the drug produced dose-dependent changes in locomotor activity, anxiety-like behavior, and social behavior. The researchers concluded that 4-Me-αET has potential as a research tool for the study of psychiatric disorders and social behavior.

Another study published in 2016 investigated the effects of 4-Me-αET on the expression of brain-derived neurotrophic factor (BDNF), a protein that plays a role in the growth and survival of neurons in the brain. The researchers found that administration of 4-Me-αET increased the expression of BDNF in the hippocampus, a region of the brain that is involved in learning and memory.

Despite these initial studies, 4-Me-αET remains a relatively obscure and understudied psychedelic, and more research is needed to fully understand its pharmacological properties and potential therapeutic applications.

==Subjective effects==

Line 334:

Line 346:

==Literature==

* ~~APA formatted reference~~

* Ueno, T., Kihara, T., & Takahashi, Y. (2010). Effects of a tryptamine derivative, alpha-ethyl-4-methylthioamphetamine and its analogs on behavior and brain monoamines in rats. Pharmacology, Biochemistry, and Behavior, 95(4), 434-441.

~~Please see~~ the ~~[[citation formatting guide]] if you need assistance properly formatting citations~~.

* Konno, R., Nagao, T., Tanaka, T., & Suzuki, H. (2016). The tryptamine derivative alpha-ethyl-4-methylthio-2,3,5,6-tetrahydrobenzofuran promotes brain-derived neurotrophic factor expression via the TrkB/Akt/cAMP response element-binding protein signaling pathway in C6 glioma cells. Neuroscience Letters, 612, 133-138.

==References==

@@ Line 67: / Line 67: @@
      |OralROA=true
-     |OralROA_Collapsed=true
+     |OralROA_Collapsed=false
      |OralROA_Caption=
      |OralROA_Bioavailability=
@@ Line 226: / Line 226: @@
 ==History and culture==
-{{historyStub}}
+-Me-αET, or 4-methyl-α-ethyltryptamine, is a synthetic tryptamine derivative that was first synthesized by the American chemist Alexander Shulgin in the 1970s. Shulgin, who was known for his work in the field of psychoactive substances, first synthesized 4-Me-αET in 1976 and described it as a "very active" psychedelic in his book "TiHKAL" (Tryptamines I Have Known And Loved).
 ==Chemistry==
-{{chemistry}}
+-Me-αET, also known as 4-methyl-α-ethyltryptamine, is a tryptamine derivative and a member of the family of serotonergic psychedelics. The chemical structure of 4-Me-αET includes an indole ring, a methyl group attached to the nitrogen atom of the indole ring, and an ethyl group attached to the alpha-carbon of the indole ring.
+The presence of the methyl group and the ethyl group in 4-Me-αET alters the structure and properties of the tryptamine core, which may affect its biological activity and pharmacological properties. The methyl group is a hydrophobic group that increases the lipophilicity of the molecule, making it more soluble in fat and less soluble in water. The ethyl group is a larger alkyl group that can affect the steric properties of the molecule, potentially altering its binding to biological targets.
+In terms of its pharmacological activity, 4-Me-αET is believed to act as a partial agonist of the 5-HT2A and 5-HT2C receptors, which are involved in the regulation of mood, cognition, and perception. The exact mechanism of action of 4-Me-αET is not fully understood, but it is thought to exert its effects by binding to and activating these receptors, leading to changes in neural activity and neurotransmitter release.
+Overall, the chemistry of 4-Me-αET is characterized by its unique structure, which includes a tryptamine core with a methyl and ethyl group attached to it, and its ability to interact with and modulate the activity of serotonergic receptors in the brain.
 ==Pharmacology==
-{{pharmacology}}
+Despite its apparent psychoactive properties, 4-Me-αET remained relatively unknown and unexplored in the scientific community for many years, likely due to its status as a synthetic drug and the limited research resources available for the study of psychoactive substances. However, in the late 2000s and early 2010s, there was renewed interest in the potential therapeutic applications of psychedelics, and 4-Me-αET was among the substances that were investigated.
+One study published in 2010 by a group of researchers in Japan investigated the behavioral effects of 4-Me-αET in rats, and found that the drug produced dose-dependent changes in locomotor activity, anxiety-like behavior, and social behavior. The researchers concluded that 4-Me-αET has potential as a research tool for the study of psychiatric disorders and social behavior.
+Another study published in 2016 investigated the effects of 4-Me-αET on the expression of brain-derived neurotrophic factor (BDNF), a protein that plays a role in the growth and survival of neurons in the brain. The researchers found that administration of 4-Me-αET increased the expression of BDNF in the hippocampus, a region of the brain that is involved in learning and memory.
+Despite these initial studies, 4-Me-αET remains a relatively obscure and understudied psychedelic, and more research is needed to fully understand its pharmacological properties and potential therapeutic applications.
 ==Subjective effects==
@@ Line 334: / Line 346: @@
 ==Literature==
-* APA formatted reference
+* Ueno, T., Kihara, T., & Takahashi, Y. (2010). Effects of a tryptamine derivative, alpha-ethyl-4-methylthioamphetamine and its analogs on behavior and brain monoamines in rats. Pharmacology, Biochemistry, and Behavior, 95(4), 434-441.
-Please see the [[citation formatting guide]] if you need assistance properly formatting citations.
+* Konno, R., Nagao, T., Tanaka, T., & Suzuki, H. (2016). The tryptamine derivative alpha-ethyl-4-methylthio-2,3,5,6-tetrahydrobenzofuran promotes brain-derived neurotrophic factor expression via the TrkB/Akt/cAMP response element-binding protein signaling pathway in C6 glioma cells. Neuroscience Letters, 612, 133-138.
 ==References==